MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1111/jdv.70154

Медицинская библиотека · Journal of the European Academy of Dermatology and Venereology : JEADV · 2025

scRNA-Seq reveals anti-lymphoma immune responses in mogamulizumab-associated skin eruptions.

Meledathu Shannon, Kurowski Agata, Naidu Malini P, Adalsteinsson Jonas, Meehan Shane A, Alkon Natalia, Port Lauren R, Chennareddy Sumanth, Cohenour Emry R, Christensen Grace, Shulman Jonah, Gulati Nicholas, Jonak Constanze, Brunner Patrick M

СтатьяПеревод в очереди

Аннотация

BACKGROUND

Mogamulizumab is an anti-CCR4 therapeutic antibody approved for relapsed or refractory mycosis fungoides, Sézary syndrome and adult T-cell leukaemia/lymphoma. During treatment, a subset of patients develops a mogamulizumab-associated drug rash (MAR) that is associated with a better overall survival, but underlying mechanisms remain unclear. In addition, misinterpretation of MAR as cutaneous T-cell lymphoma (CTCL) progression can lead to unnecessary drug discontinuation.

OBJECTIVES

To conduct a comprehensive molecular characterization of MAR.

METHODS

We performed single-cell RNA sequencing of skin biopsies from 4 patients with MAR, compared to untreated erythrodermic CTCL (CTCL, n = 6) and healthy control (HC, n = 4) skin.

RESULTS

CCR4 was primarily expressed in proliferating and non-proliferating malignant T-cell clones and FOXP3+ regulatory T cells in untreated CTCL, which were significantly decreased in MAR. The few residual malignant clones in MAR showed retained CCR4 expression, but decreases in the central memory markers SELL and CCR7, with upregulation of the MMP2 inhibitor TIMP2 and the tumour suppressor gene RUNX3, consistent with a more silenced immune phenotype. In parallel, polyclonal T cells in MAR lesions exhibited decreases in the exhaustion markers TIGIT and TOX, paralleled by upregulation of markers associated with cytotoxicity (GZMA) and anti-cancer properties (ZNF683). This increase in tumour suppressor and cytotoxicity genes potentially reflects an anti-lymphoma immune response within the MAR skin microenvironment.

CONCLUSIONS

Our study provides novel insights into the molecular properties of residual malignant clones within MAR that appear silenced, surrounded by a putatively anti-tumor immune response.

Для цитирования: Meledathu Shannon, Kurowski Agata, Naidu Malini P, Adalsteinsson Jonas, Meehan Shane A, Alkon Natalia, Port Lauren R, Chennareddy Sumanth, Cohenour Emry R, Christensen Grace, Shulman Jonah, Gulati Nicholas, Jonak Constanze, Brunner Patrick M. scRNA-Seq reveals anti-lymphoma immune responses in mogamulizumab-associated skin eruptions.. Journal of the European Academy of Dermatology and Venereology : JEADV. 2025. DOI: 10.1111/jdv.70154.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.